H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assay...
The proprietary GPC3 targeting peptide is being licensed from RayzeBio pursuant to an existing license agreement. Upon in-license of product candidates by ...
Under Scivita Medical's comprehensive product lineup of reusable endoscopes, single-use videoscopes and related systems and equipment, this cooperation fur...
TandemAI today announced the release of TandemViz™ 1.0, the company’s proprietary web-based platform that provides its growing roster of drug d...
Artificial intelligence continues to expand rapidly and a new computer vision algorithm is now available to Moscow radiologists in city hospitals. It analy...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agr...
Survey of 7,000+ people in Asia shows expectation of early retirement, early deterioration in health Concerns about cost of well-being nu...
Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health Univer...
ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...
BetaLife has acquired the rights to human iPSC technology and cell lines from A*STAR BetaLife and A*STAR sign research collaboration agreement to jointl...
Curia, a leading contract research, development and manufacturing organization, today announced a collaboration with Corning Incorporated to expand and acc...
HANSIZHUANG (serplulimab) is the first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC) The EC and the FDA previously granted...
Orion Health, a global leader in population health software, is strengthening its position in North America with new technology and the appointment of Jame...
ProfoundBio, a clinical stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential, will present t...
© 2025 Biopharma Boardroom. All Rights Reserved.
